Synthetic hexapeptide GHRP
Hexarelin
Potent GHRP and ghrelin-receptor agonist for strong GH secretion.
- Half-life~30 minutes plasma
- Dose range100 to 200 mcg per administration, 1 to 2 times daily · 4 to 6 week cycle
- Reconstituted stability28 days, 2–8 °C
- VerificationCOA included
Mechanism
How it works.
Potent GHSR-1a receptor agonist. Direct cardioprotective effects in research models, separate from GH-release pathway.
Research
What the research shows.
Strongest GH-release in the GHRP class. Cardiovascular research suggests direct cardioprotective effects. Cycle patterns kept tight due to tolerance development.
Hexarelin is a synthetic hexapeptide ghrelin-receptor agonist with the strongest raw GH-release potency in the GHRP class. Tolerance can develop with continuous use, which is why cycle patterns are tighter than for Ipamorelin.
Research-context use focuses on aggressive GH-research protocols. The cardiovascular research base on Hexarelin is meaningful, the compound has been studied for cardiac protective effects beyond the GH-release context.
Contraindications
When not to use.
Active malignancy. Pregnancy. Pediatric use without clinical oversight.
Information is educational, derived from published research. Not medical advice. All compounds sold for research use only. Bloodwork and a clinical consultation should precede any new protocol.